IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. by Kuijjer, M, Peterse, E, van den Akker, B, Briaire-de Bruijn, I, Serra, M, Meza-Zepeda, L, Myklebost, O, Hassan, A, Hogendoorn, P, Cleton-Jansen, A

Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. by Lenos, K, Grawenda, A, Lodder, K, Kuijjer, M, Teunisse, A, Repapi, E, Grochola, L, Bartel, F, Hogendoorn, P, Wuerl, P, Taubert, H, Cleton-Jansen, A, Bond, G, Jochemsen, A